Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4635794
Max Phase: Preclinical
Molecular Formula: C50H60N10O7S
Molecular Weight: 945.16
Molecule Type: Unknown
Associated Items:
ID: ALA4635794
Max Phase: Preclinical
Molecular Formula: C50H60N10O7S
Molecular Weight: 945.16
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCOCCN2CCC(n3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C50H60N10O7S/c1-32-44(68-31-55-32)35-12-10-33(11-13-35)27-52-48(63)40-26-37(61)28-59(40)49(64)45(50(2,3)4)56-41(62)29-66-25-24-65-23-22-58-20-18-36(19-21-58)60-47-42(46(51)53-30-54-47)43(57-60)34-14-16-39(17-15-34)67-38-8-6-5-7-9-38/h5-17,30-31,36-37,40,45,61H,18-29H2,1-4H3,(H,52,63)(H,56,62)(H2,51,53,54)/t37-,40+,45-/m1/s1
Standard InChI Key: RIOHYDUGYNZWPD-DIKPJKDTSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 945.16 | Molecular Weight (Monoisotopic): 944.4367 | AlogP: 5.78 | #Rotatable Bonds: 18 |
Polar Surface Area: 212.18 | Molecular Species: BASE | HBA: 15 | HBD: 4 |
#RO5 Violations: 3 | HBA (Lipinski): 17 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.13 | CX Basic pKa: 8.93 | CX LogP: 3.47 | CX LogD: 1.92 |
Aromatic Rings: 6 | Heavy Atoms: 68 | QED Weighted: 0.08 | Np Likeness Score: -0.87 |
1. Jaime-Figueroa S, Buhimschi AD, Toure M, Hines J, Crews CM.. (2020) Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties., 30 (3): [PMID:31879210] [10.1016/j.bmcl.2019.126877] |
Source(1):